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Abstract 
Background: Cryptosporidium is a major cause of diarrhea worldwide in both humans and farm animals with no 
completely effective treatment available at present. In this study, we assessed the inhibitory effect of different concen-
trations of Auranta 3001 (0.1, 0.5 and 1%), a novel natural feed supplement, on C. hominis and C. parvum invasion of 
human ileocecal adenocarcinoma (HCT-8), bovine primary cells and C. parvum invasion of HCT-8, bovine primary cells 
and bovine intestinal biopsies. The effect of the feed supplement on the production of pro-inflammatory cytokines 
IL-8 and INF-γ, the anti-inflammatory cytokine IL-10, the expression of CpSUB1 protease gene during infection was 
also assessed by quantitative PCR (q-PCR). Transepithelial electrical resistance (TEER) was employed to measure the 
integrity of tight junction dynamics of the culture models.
Results: Pre-treatment of intestinal cells or oocysts with the Auranta 3001 significantly reduced the invasiveness of C. 
hominis and C. parvum against HCT-8 and bovine primary cells in a dose dependent manner. The most pronounced 
reduction in the invasiveness of both parasites was observed when Auranta 3001 was present during infection. Levels 
of IL-8 were significantly reduced in both HCT-8 and bovine primary cells, while the levels of INF-γ and IL-10 showed 
opposite trends in the two cell lines during infection in the presence of Auranta 3001. CpSUB1 gene protease expres-
sion, which mediates infection, was significantly reduced suggesting that this enzyme is a possible target of Auranta 
3001.
Conclusions: Although, C. hominis and C. parvum use different invasion mechanisms to infect cells, the novel feed 
additive can significantly attenuate the entry of Cryptosporidium in HCT-8 cells, primary bovine cells and bovine intes-
tinal biopsies and thus provide an alternative method to control cryptosporidiosis.
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Background
Cryptosporidium is a protozoan parasite of public health 
and veterinary significance that causes gastroenteritis in 
a range of vertebrate hosts. The majority of human infec-
tions are attributed to C. hominis, which humans as the 
only natural hosts and C. parvum which infects mostly 
mammals, including humans [1]. The infection is transmit-
ted mainly by the fecal–oral route, and is initiated when 
sporozoites are released from oocysts present in water or 
food or by direct contact with an infected person or animal 
[2]. Cryptosporidium infection ultimately results is epithe-
lial cell death thus leading to villous atrophy, malabsorption 
and distorted intestinal permeability, all of which contrib-
utes to the occurrence of watery diarrhea [3]. The host’s 
immune state has a key role in determining susceptibil-
ity to infection as well as the severity of cryptosporidiosis. 
In healthy people, cryptosporidiosis is self-limiting and 
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gastrointestinal symptoms usually resolve spontaneously 
within 1–2 weeks, although asymptomatic carriage might 
occur. Nevertheless, in immunocompromised patients, 
severe watery diarrhea can develop which can lead even to 
death [4]. In tropical countries, Cryptosporidium caused 
diarrhea can result in impaired childhood development [5]. 
Numerous human cryptosporidiosis outbreaks have been 
identified on a global scale. The most extensive outbreak 
was recorded in 1993 in Milwaukee, U.S.A., during which 
approximately 400,000 people were infected with Crypto-
sporidium oocysts by drinking contaminated water. An 
increase in Cryptosporidium infections was also reported 
in Germany, United Kingdom and the Netherlands in 2012 
[6]. In Asia and Africa, cryptosporidiosis is now consid-
ered the second most common cause of diarrhea [7]. Even 
though promising chemotherapeutic treatments against 
cryptosporidiosis are beginning to appear, no consistently 
effective treatments exist for humans and animals [8, 9]. 
Paromomycin and Nitazoxanide have been used but results 
showed limited efficacy against cryptosporidiosis and 
sometimes relapse of diarrhea has been observe [10, 11]. 
Halofuginone lactate is another anticoccidial agent used 
against cryptosporidiosis and although it diminishes oocyst 
shedding and the severity of the diseases, in calves, it does 
not result in a complete cure [12, 13].
Considering the potential side effects of and resist-
ance to many drugs, attention has shifted towards plant 
extracts. Plants represent an excellent source of bioactive 
compounds and have a long history in the prevention as 
well as treatment of a range of human and animal diseases 
[14]. Therefore, interest in natural products with antipara-
sitic properties has increased in recent years. Curcumin 
has showed promising effects against C. parvum in vitro 
[15]. Also, the ethanolic extract from olive pomace has 
been shown to effectively inhibit C. parvum development 
[14]. Therefore, there is a great need to develop new anti-
cryptosporidial agents, in order to provide an alternative 
method to control cryptosporidiosis. The present study 
aimed at investigating the antiparasitic effectiveness of 
the experimental natural feed supplement Auranta 3001 
in the prevention C. homins and C. parvum infections in 
human and primary bovine cell models.
Methods
Parasites
Cryptosporidium parvum (G1) and C. hominis (G2) 
oocysts were obtained from American Type Culture Col-
lection and stored in phosphate-buffered saline (PBS) at 
4 °C until use. For cell culture assays oocysts were incu-
bated for 15 min in sodium hypochlorite (4%) at 4 °C and 
washed three times with cold D-PBS (Dulbecco’s phos-
phate buffered saline, Sigma, UK) followed by centrifuga-
tion for 10 min at 2500×g. The pellet was suspended in 
1 ml D-PBS and oocysts were counted in a haemocytom-
eter. Prior to use, oocysts were un-treated or treated with 
0.1, 0.5 or 1% Auranta A3001 and then washed five times 
with 20 mM PBS by centrifugation at 6000g for 3 min at 
4 °C.
HCT‑8 epithelial cells and isolation of bovine 
gastrointestinal cells
Human ileocecal adenocarcinoma cells (HCT-8) were 
obtained from the American Type Culture Collection 
and maintained as previously described [16]. Bovine 
cells were prepared as previously described [17]. Briefly 
small duodenal tissue was placed in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma, UK) media containing 
10% FBS (Fetal Bovine Serum), 100 μg of streptomycin/
ml, 100 U of penicillin/ml, and 2.5  μg of amphotericin 
B (Sigma, UK)/ml. The tissue was incubated at 37  °C 
for 10  min with vigorous shaking. The supernatant was 
removed, and the tissue was placed in DMEM media 
containing 0.05% (wt/vol) collagenase (Sigma) and incu-
bated at 37 °C for 15 min with vigorous shaking. The iso-
lated cells and crypts were kept on ice until 500  μl was 
plated in 24-well Costar culture plates on 13-mm plastic 
coverslips with Dulbecco modified Eagle medium-Ham 
F-12 plus 10% (vol/vol) FBS, 8 μg of insulin/ml, 10 μg of 
gentamicin/ml, 50  μg of hydrocortisone/ml, 100  μg of 
streptomycin/ml, 100 U of penicillin/ml, and 2.5  μg of 
amphotericin B/ml.
Infection of HCT‑8 cells and primary—bovine intestinal 
cells
A concentration of 1.5  ×  107 Cryptosporidium oocysts 
(G1 or G2) was added to the isolated bovine cells or cul-
tured HCT-8 cells as previously described [18]. There 
were three types of infection assays performed in order 
to test the efficiency of this antimicrobial product. First, 
the oocysts were pre-treated with Auranta A3001 (0.1, 
0.5 and 1%), for 1 h, and washed in maintenance media 
prior to cell infection, secondly the cells were treated for 
1 h prior the infection assays or the antimicrobial was 
present in the media during infection. For infection, the 
medium was removed from the host cell culture and 
replaced with 5 ml of oocyst suspension. As positive con-
trol, 1  μg/ml cytochalasin D was used as pre-treatment 
of cells before infection. The flasks were placed at 37  °C 
in a 5%  CO2–95%. After incubation for 3 h, the infected 
cells were washed with D-PBS followed by the addition 
of 2  ml growth medium containing 100 U of penicillin/
ml and 100 g of streptomycin/ml was added. Primary cells 
and HCT-8 cells were infected for up to 18 h. During this 
time period the cells remained viable and did not appear 
to be damaged by infection. The parasites were detected 
and counted in monolayers using lectin VVL staining 
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as previously described [17]. After incubation for 4  h at 
37 °C in 5%  CO2 to allow attachment and penetration of 
sporozoites, the monolayers were washed with DMEM 
to remove non-invasive sporozoites, residual oocysts and 
non-adherent epithelial cells, and 5  ml of new growth 
medium with or without antimicrobial agents was added. 
Infected cell cultures were kept at 37 °C in 5%  CO2. Exper-
iments were performed in triplicates and expressed as the 
mean percentage of cells infected. The bovine biopsies 
were obtained from a local abattoir and infected following 
same procedure. Infected biopsies were fixed in formalin 
for 24 h and snapped freeze in liquid nitrogen. The IL-8, 
INF-γ and IL-10 supernatant concentration for each well 
was determined, at 18  h, by using a commercially avail-
able enzyme-linked immunosorbent assay systems from 
Quantikine, R&D Systems at 1% Auranta 3001. Results of 
cytokine concentration were expressed as pg (pictograms) 
per milliliter of culture medium. Each study run included 
wells with no parasite in the HCT-8 cell or bovine culture 
assay. All samples were analyzed in triplicate.
q‑PCR
Cryptosporidium G1 and G2 oocysts (2 × 105 per flask) 
were used to infect confluent HCT-8 cell monolayers or 
isolated bovine intestinal cells grown in T-25 tissue cul-
ture flasks. Total RNA was isolated from infected and 
uninfected HCT-8 cells at 0, 6, 12 and 18 h postinfection, 
using an RNeasy kit (Qiagen-UK) and was reverse tran-
scribed to cDNA by using the Superscript first-strand 
system (Roche, UK). cDNA was amplified by PCR for 35 
cycles (94  °C for 1  min, 64  °C for 1  min, and 72  °C for 
1.5  min), using primers (CpSUB1-F-AAAGGATCT 
GGAGTATATTAT and CpSUB1-R-AATATTTAATGT 
CCCAGAGG) [16]. Uninfected cells were used as con-
trol. The PCR reactions were set using SYBR Green Mas-
ter mix (Applied Biosystems, UK).
TEER
To investigate the effect of C. parvum G1 and G2 on the 
barrier properties HCT-8 cells and isolated bovine cells, 
transepithelial electrical resistance (TEER) was measured 
at 3  h postinfection using an EVOM X meter (World 
Precision Instruments) coupled to an Endohm chamber 
(World Precision Instruments), and the infected cells 
compared to noninfected cells whose TEER was also 
measured at 3 h following infection.
Results
In vitro and ex vivo effect of Auranta 3001 on invasiveness 
of C. hominis and C. parvum to HCT‑8 cells, primary bovine 
intestinal cells and bovine intestinal biopsies
The invasiveness of C. hominis (G1) and C. parvum 
(G2) was quantified. Pre-treatment of host cells with 
cytochalasin D (CyD) significantly reduced invasion 
of C. hominis and C. parvum into human and primary 
bovine cells (Figs. 1, 2) due to disruption of the host actin 
cytoskeleton. Results from the invasion assays showed 
that both parasites were able to invade HCT-8 cells and 
primary bovine intestinal cells with a similar efficiency 
(Figs.  1, 2). Pre-treatment of HCT-8 cells with different 
concentrations of the novel feed supplement reduced 
invasion of primary bovine cells and HCT-8 cells by C. 
hominis and C. parvum in a dose dependent manner. The 
same potent inhibition of infection was observed when 
of oocysts of both parasite species were pre-treated with 
increasing concentrations of Auranta 3001. Comparing 
the invasiveness of the two parasites in the bovine cell 
model, it is noteworthy that in both the pre-treatment 
of intestinal cells and oocysts, C. parvum invasiveness 
was significantly lower compared to the invasiveness of 
C. hominis. This phenomenon was not observed with the 
HCT-8 cells with both parasites showing similar inva-
siveness. To extend the above observations, invasiveness 
efficiency of both parasites was determined, without pre-
treatment, when the feed supplement was present during 
infection. In this case, the effectiveness of Auranta 3001 
in decreasing Cryptosporidium invasiveness was even 
more pronounced, reaching approximately 60–70%, even 
at the lower supplement concentrations (0.1%). Similar 
effects of Auranta 3001 were observed when the C. par-
vum infection of bovine intestinal biopsies was investi-
gated (Fig. 3) suggesting clearly its potential in reducing 
the virulence of this parasite.
Protection against disassembly of cellular tight junctions 
by Auranta 3001
The transepithelial electrical resistance (TEER) was 
measured to assess the changes in the integrity of tight 
junctions and permeability in the cell monolayers. Fig-
ures 1d and 2d show that low TEER values were obtained 
after a 3  h infection, which suggests dysfunction of the 
epithelial barrier during the in vitro intestinal infections 
with both parasites and both epithelial cell models. How-
ever, when Auranta 3001 was present in the medium dur-
ing infection a significant increase in TEER was observed. 
Importantly, TEER values increased as the concentration 
of the feed supplement increased.
Effect of Auranta 3001 on the levels of IL‑8, IFN‑γ and IL‑10
In this study, three different types of cytokines (IL-8, 
IFN-γ and IL-10) where investigated. Bacterial cell wall 
lipopolysaccharide (LPS) was used as a positive control 
because this endotoxin is a prototypic microbial trigger 
that stimulates innate immunity. The resultant inflam-
matory responses are essential in early host defense 
but may also contribute to later organ injury [19]. The 
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cytokine IL-8 levels were examined after an 18 h incuba-
tion (Fig.  4a, b). In HCT-8 cells, the secretion, in  vitro, 
showed decreased IL-8 levels (approx. 350 pg/ml reduc-
tion for C. hominis (p  <  0.0001) and approx. 250  pg/ml 
for C. parvum (p ≤  0.001)) when the cells were treated 
with Auranta 3001. In primary bovine intestinal cells, 
the same trend was observed, with the IL-8 levels being 
reduced by more than 100  pg/ml for both parasites 
(p  <  0.0001). Similar results were obtained with LPS 
treated HCT-8 and primary bovine cells. The levels of 
the immunomodulatory cytokine IFN-γ (Fig. 4c, d) were 
not influenced by the feed supplement in HCT-8 cells, 
whereas in primary bovine cells, the levels of IFN-γ 
increased by approximately 900  pg/ml (p  <  0.001) for 
both HCT-8 and primary bovine infected cells. LPS treat-
ment increased levels of IFN-γ in both cell models but 
Auranta 3001 did not have an effect on the levels of IFN-
γ. The immunosuppressive cytokine IL-10, (Fig.  4e, f ) 
showed a pronounced increase in HCT-8 cells, when they 
were incubated with Auranta 3001, (p < 0.0001) showing 
that the feed supplement has a great capacity in suppress-
ing the inflammatory process. In primary bovine cells the 
levels of IL-10 did not differ significantly between the 
control and the Auranta 3001 treated ones. LPS treated 
HCT-8 and primary bovine cells showed the same trend.
Effect of Auranta 3001 on expression of CpSUB1, a 
subtilisin‑like protease, in C. parvum during infection
Figure  5a, b present the quantification of CpSUB1 
expression at different times in C. parvum infected 
HCT-8 cells and primary bovine cells, respectively. qPCR 
of RNA from both cell models infected with C. parvum 
for increasing periods of time revealed that the CpSUB1 
gene is expressed throughout infection. When HCT-8 
cells and primary bovine cells were treated with increas-
ing concentrations of the natural feed supplement, 
CpSUB1 gene expression was significantly reduced dur-
ing the course of infection in vitro.
Fig. 1 Effect of different concentrations of Auranta 3001 on Cryptosporidium invasiveness in HCT-8 cells. a HCT-8 cells exposed to different concen-
trations of Auranta 3001 for 1 h prior to infection. b Cryptosporidium oocysts exposed to different concentrations of Auranta 3001 for 1 h prior to 
infection. c Auranta 3001 present in the medium during infection. d Transepithelial electrical resistance (TEER) values of non-treated cells and cells 
treated with Auranta 3001. Asterisks indicate significant differences (*p < 0.05; **p < 0.01; ***p < 0.001). Error bars represent the standard deviation of 
means from three different experiments. G1, Cryptosporidium hominis; G2, Cryptosporidium parvum; CyD, cytochalasin D
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Discussion
In order to tackle the issue of the lack of effective thera-
peutic agents against Cryptosporidiosis, we explored the 
efficiency of Auranta 3001, a natural feed supplement, 
against C. hominis and C. parvum in  vitro. Preliminary 
results revealed that the feed supplement was toxic to 
HCT-8 bovine cells at concentrations higher than 1%. 
Lower concentrations had insignificant effects on both 
of the cell models and thus concentrations up to 1% were 
investigated.
It has been reported that different Cryptosporidium 
species utilise different mechanisms to infect cells of dif-
ferent origins [17] therefore anti-Cryptosporidium agents 
able to effectively prevent invasion in different host cells 
would be of great benefit. In the present study, C. hominis 
and C. parvum is able to effectively invade both HCT-8 
and primary bovine cells. To evaluate the effect on par-
asite invasiveness, the feed supplement was applied at 
different concentrations to C. hominis and C. parvum 
oocysts for 1  h before infection. Pre-treatment of the 
oocysts resulted in statistically significant reductions 
(p < 0.01–0.001) in the invasiveness for both HCT-8 and 
bovine cells with the reduction being more pronounced 
with increasing supplement concentrations. It is note-
worthy that although the invasiveness of C. hominis and 
C. parvum was similar for the HCT-8 cells, it showed dif-
ferences in the bovine cells with C. parvum invasiveness 
being significantly lower compared to the HCT-8 cell line 
(Figs. 1a, 2a).
Potentially the novel feed supplement can also interfere 
with host cell metabolic pathways, which subsequently 
affect parasite infection and growth. To address this pos-
sibility, HCT-8 cells and bovine cells were pre-treated 
with the feed supplement for 1 h and then infected with 
C. hominis or C. parvum in the absence of the supple-
ment. The pre-treatment of host cells with increasing 
concentrations of Auranta 3001 (0.1–1%), lead to a sig-
nificant inhibition of invasiveness for both parasites 
Fig. 2 Effect of different concentrations of Auranta 3001 on Cryptosporidium invasiveness in primary bovine cells. a Primary bovine cells exposed to 
different concentrations of Auranta 3001 for 1 h prior to infection. b Cryptosporidium oocysts exposed to different concentrations of Auranta 3001 
for 1 h prior to infection. c Auranta 3001 present in the medium during infection. d Transepithelial electrical resistance (TEER) values of non-treated 
cells and cells treated with Auranta 3001. Asterisks indicate significant differences (*p < 0.05; **p < 0.01; ***p < 0.001). Error bars represent the stand-
ard deviation of means from three different experiments. G1, Cryptosporidium hominis; G2, Cryptosporidium parvum; CyD, cytochalasin D
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Fig. 3 Lectin VVL staining of bovine intestinal biopsies infected with C. parvum. Effect of different concentrations of Auranta 3001 on C. parvum 
ex vivo infection of bovine intestinal biopsies
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Fig. 4 Cytokine expression in HCT-8 and primary bovine intestinal cells during infection with LPS and C. hominis and C. parvum. All of the cells were 
cultured to 80–90% confluency and challenged (infected) with C. hominis and C. parvum for 18 h. a IL-8 levels of HCT-8 cells. b IL-8 levels of primary 
bovine cells. c IFN-γ levels of HCT-8 cells. d IFN-γ levels of primary bovine cells. e IL-10 levels of HCT-8 cells (f) IL-10 levels of primary bovine cells. 
LPS treated HCT-8 and primary bovine cells were used as positive controls. Not treated HCT-8 and primary bovine were used a negative controls. 
Asterisks indicate significant differences (***p < 0.001; ****p < 0.0001). Error bars represent the standard deviation of means from three different 
experiments. G1, Cryptosporidium hominis; G2, Cryptosporidium parvum
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(Figs.  1b, 2b). In this case too, C. parvum invasiveness 
in bovine cells was significantly lower compared to the 
HCT-8 cells.
Natural extracts have been employed in other studies 
against Cryptosporidium. Garlic juice (Allium sativum) 
has been shown to significantly reduce Cryptosporidium 
oocysts from stool of immunosuppressed mice without 
affecting intestinal architecture [10]. Curcumin, a natu-
ral polyphenolic compound, although does not reduce 
viability of C. parvum it can attenuate invasiveness in 
HCT-8 cells by 65% at a concentration of 200  μM [15]. 
Pomegranate extract (3.75%) supplemented in milk has 
also shown to reduce fecal oocyst count and diarrhea 
intensity and duration in neonatal calves [20]. Although 
C. hominis and C. parvum possess different pathways to 
infect different host cells [17], the results presented here 
revealed that the natural feed supplement is a potent 
inhibitor of C. hominis and C. parvum invasiveness in 
both human and primary bovine cells.
The cytokine profile of HCT-8 and primary bovine 
cells was also determined in order to investigate the host 
immune response to the natural feed supplement. The 
immune defence mechanism of an immunocompetent 
host against Cryptosporidium spp. used to recover from 
Cryptosporidium spp. infection involves both functional 
cellular and humoral immunities, but the actual mecha-
nism is still unknown. Studies have shown that IL-8 is 
expressed after Cryptosporidium spp. in  vitro infection 
of intestinal cell lines and human intestinal xenographs 
[21]. In the present study, exposure to Auranta 3001 sig-
nificantly decreased the IL-8 levels, which suggests that 
Auranta 3001 is not recognized as a pathogenic signal by 
both HCT-8 cells and primary bovine cells indicating the 
anti-inflammatory role for Auranta 3001 in the gastro-
intestinal tract inflammation during Cryptosporidium 
spp. infection. Also, IFN-γ results showed that Auranta 
3001 did not have any effect on IFN-γ production in 
HCT-8 cells, keeping concentrations at similar levels with 
the controls, whereas in bovine primary cells, the levels 
of IFN-γ were significantly increased, showing its effec-
tiveness in mediating the immune response in this type 
of cells when infected with C. hominis and C. parvum. 
Studies have shown that the immune response towards 
Cryptosporidium in humans differs from that in animals. 
IFN-γ production in mice seems to be linked with the 
innate and primary immune responses [22], whereas in 
humans it is probably related with the memory response 
towards the parasite. Even though IFN-γ has been shown 
to play an important role in both the innate and adap-
tive immune responses to C. hominis and C. parvum, 
the mechanisms of resistance mediated by this cytokine 
alone are not completely understood yet [21]. Interleu-
kin-10 plays a major role in the resolution of inflamma-
tion during sepsis and infection but is also involved in 
persistence of pathogens by interfering with innate and 
adaptive immunity [23]. The Auranta 3001 results on 
HCT-8 cells, revealed its anti-inflammatory properties. 
The levels of IL-10 in HCT-8 cells increased significantly 
during infection with C. hominis and C. parvum. On the 
other hand, the supplement did not have any effect on 
IL-10 production in primary bovine cells, with the levels 
of this cytokine remaining at similar concentrations with 
the controls.
Parasite proteases are of particular importance since 
they are involved in the proteolysis of surface and api-
cal proteins that mediate invasion [24, 25]. A number 
Fig. 5 Effect of different concentrations of Auranta 3001 on CpSUB1 expression in C. parvum infected HCT-8 and primary bovine cells. a C. parvum 
infected HCT-8 cells (b) bovine primary cells. qPCR was performed on total RNA extracted from C. parvum cells at different time intervals during 
infection. Asterisks indicate significant differences (**p < 0.01; ***p < 0.001). Error bars represent the standard deviation of means from three different 
experiments
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of these proteins are processed by serine proteases. Evi-
dence from the use of protease inhibitors has suggested 
that serine proteases might be essential for host cell 
infection by C. parvum infection in vitro [26, 27].
Genes expressing serine proteases have been identified 
for Cryptosporidium [28, 29]. In order to better under-
stand the antiparasitic mechanism of the natural feed sup-
plement, in this study, we focused on the subtilisin-like 
serine protease CpSUB1 involved in the proteolytic cleav-
age of Cryptosporidium gp40/15 to produce the surface 
glycopeptides gp40 and gp15 which are involved in infec-
tion [27]. In the present study, qPCR results showed that 
the CpSUB1 gene in C. parvum is expressed throughout 
infection which is consistent with the study of Wanyiri 
et  al. [16] in which a semi-quantitative determination 
was employed. Specific quantification of CpSUB1 gene 
revealed that when infection of both HCT-8 and primary 
bovine cells took place in the presence of different con-
centrations of the natural supplement expression was sig-
nificantly reduced at all the concentrations used and at 
all time points investigated during infection (Fig.  5a, b). 
These results in combination with the fact that the natu-
ral supplement significantly inhibited C. parvum infection 
of HCT-8 cells in a dose-dependent manner compared to 
untreated controls shows that subtilisin-like serine pro-
tease CpSUB1 is targeted by the natural feed supplement 
leading to decreased invasion. However, it is possible that 
the natural supplement might exert an effect on other tar-
gets as well. Although, the expression of subtilase protease 
gene for C. hominis (ChSUB1) was not studied here, it has 
been shown that ChSUB1 and CpSUB1 are 98% identical 
with the alignment of the CpSUB1 and ChSUB1 nucleo-
tide sequences identifying primarily silent substitutions 
[28]. Therefore, based on the significantly reduced inva-
siveness of C. hominis observed, we hypothesised that 
ChSUB1 is a target for the natural feed supplement as well.
Disruption of cell tight junctions is known to con-
tribute to intestinal diseases by enteric pathogens [30]. 
TEER values are considered strong indicators of cellu-
lar barrier integrity [31]. In  vitro studies have shown a 
rapid decrease in TEER as one of the characteristics of 
Cryptosporidiosis [32, 33]. In this study, infection with C. 
hominis and C. parvum resulted in low TEER values for 
both HCT-8 and bovine cells which corresponds to dis-
rupted tight junction architecture and barrier function. 
However, in the presence of the novel supplement sig-
nificantly higher TEER values were observed showing the 
protective effect of Auranta 3001 on both cell monolay-
ers (Figs.  1d, 2d). Protein kinace C (PKC) mediates cal-
cium-induced tight junction assembly and its inhibition 
has been found to stop the normal distribution of tight 
junction-associated proteins such as ZO-1 and cingulin 
[34]. A possible explanation of the reduced invasiveness 
observed is that exposure of HCT-8 and primary bovine 
cells to the feed supplement during infection caused 
stimulation of tight junctions in the host cells by inhibit-
ing PKC although further studies are needed to confirm 
this.
Conclusions
In conclusion, we found that the Auranta 3001 is able to 
significantly reduce the invasiveness of C. hominis and 
C. parvum and protect host cells in  vitro. It was also 
shown that the natural feed supplement induced dif-
ferent host cell response in HCT-8 and primary bovine 
cells, and its activity is exerted, at least partly, by inhib-
iting CpSUB1 gene expression. Based on these results, 
Auranta 3001 shows great potential as a method to con-
trol cryptosporidiosis.
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